
131.03 Delayed Data As of Sep 28 | ![]() Today’s Change | 120.64 Today|||52-Week Range 160.96 | -17.75% Year-to-Date |
Ligand (LGND) Acquires Certain Assets of Novan for $12.2M Sep 28 / Zacks.com - Paid Partner Content | Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View Sep 19 / Zacks.com - Paid Partner Content |
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze Sep 22 / Zacks.com - Paid Partner Content |
Previous close | 131.23 |
Today’s open | 131.34 |
Day’s range | 130.84 - 132.42 |
Volume | 683,645 |
Average volume (3 months) | 542,214 |
Market cap | $8.3B |
Earnings growth (last year) | +35.13% |
Earnings growth (this year) | +32.57% |
Earnings growth (next 5 years) | +13.00% |
Revenue growth (last year) | +18.26% |
P/E ratio | NM |
Price/Sales | 2.72 |
Price/Book | 2.69 |
Next reporting date | November 7, 2023 |
EPS forecast (this quarter) | $4.56 |
Annual revenue (last year) | $3.7B |
Annual profit (last year) | -$224.1M |
Net profit margin | -6.12% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Dublin, Dublin |